Metastatic colorectal cancer first-line treatment with bevacizumab: the impact of K-ras mutation

BACKGROUND: Bevacizumab plus chemotherapy prolongs progression-free survival (PFS) and overall survival (OS) in metastatic colorectal cancer (mCRC). Although there is strong evidence to suggest that the mutational status of the K-ras oncogene has a role as a predictive factor for activity in patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Rossi, Luigi, Veltri, Enzo, Zullo, Angelo, Zoratto, Federica, Colonna, Maria, Longo, Flavia, Mottolese, Marcella, Giannarelli, Diana, Ruco, Luigi, Marchetti, Paolo, Romiti, Adriana, Barucca, Viola, Giannini, Giuseppe, Bianchi, Loredana, Tomao, Silverio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3848929/
https://www.ncbi.nlm.nih.gov/pubmed/24348051
http://dx.doi.org/10.2147/OTT.S43828

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3848929/
https://www.ncbi.nlm.nih.gov/pubmed/24348051
http://dx.doi.org/10.2147/OTT.S43828

Ejemplares similares